INNOVENT BIOLOGICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.4 HKD | +2.10% |
|
-1.08% | -3.16% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 29,957 | 96,872 | 57,482 | 45,398 | 63,018 | 62,290 | - | - |
| Enterprise Value (EV) 1 | 26,589 | 89,793 | 50,957 | 39,338 | 63,018 | 57,264 | 57,922 | 57,673 |
| P/E ratio | -16.3 x | -93.3 x | -18.2 x | -20.3 x | - | -72.6 x | 342 x | 43.2 x |
| Yield | - | - | - | - | - | - | 0.01% | - |
| Capitalization / Revenue | 28.6 x | 25.2 x | 13.5 x | 9.96 x | 10.2 x | 8.22 x | 6.26 x | 4.81 x |
| EV / Revenue | 25.4 x | 23.4 x | 11.9 x | 8.63 x | 10.2 x | 7.56 x | 5.82 x | 4.45 x |
| EV / EBITDA | -16.2 x | -370 x | -16.7 x | -14.3 x | -105 x | -122 x | 100 x | 32 x |
| EV / FCF | -13.1 x | -113 x | -16.5 x | -14 x | - | -60.4 x | -253 x | 53.8 x |
| FCF Yield | -7.64% | -0.89% | -6.06% | -7.16% | - | -1.66% | -0.4% | 1.86% |
| Price to Book | 5.87 x | 10.7 x | 5.54 x | 4.11 x | - | 5.07 x | 5.22 x | 4.77 x |
| Nbr of stocks (in thousands) | 1,262,562 | 1,402,776 | 1,462,109 | 1,534,407 | 1,621,831 | 1,627,102 | - | - |
| Reference price 2 | 23.73 | 69.06 | 39.31 | 29.59 | 38.86 | 38.28 | 38.28 | 38.28 |
| Announcement Date | 3/30/20 | 3/29/21 | 3/29/22 | 3/28/23 | 3/20/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,048 | 3,844 | 4,270 | 4,556 | 6,206 | 7,578 | 9,952 | 12,949 |
| EBITDA 1 | -1,638 | -242.4 | -3,045 | -2,747 | -600.1 | -467.6 | 578.4 | 1,799 |
| EBIT 1 | -1,676 | -310.4 | -3,113 | -3,066 | - | -927.7 | 110.8 | 1,622 |
| Operating Margin | -159.96% | -8.08% | -72.9% | -67.29% | - | -12.24% | 1.11% | 12.53% |
| Earnings before Tax (EBT) 1 | -1,720 | -858.7 | -3,051 | -2,170 | - | -818.3 | 215.5 | 1,726 |
| Net income 1 | -1,720 | -998.4 | -3,138 | -2,179 | - | -844.5 | 147.3 | 1,442 |
| Net margin | -164.2% | -25.97% | -73.5% | -47.83% | - | -11.14% | 1.48% | 11.14% |
| EPS 2 | -1.460 | -0.7400 | -2.160 | -1.460 | - | -0.5270 | 0.1119 | 0.8860 |
| Free Cash Flow 1 | -2,030 | -796.7 | -3,090 | -2,816 | - | -948.8 | -228.8 | 1,072 |
| FCF margin | -193.83% | -20.73% | -72.38% | -61.8% | - | -12.52% | -2.3% | 8.28% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 59.59% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 74.37% |
| Dividend per Share 2 | - | - | - | - | - | - | 0.003330 | - |
| Announcement Date | 3/30/20 | 3/29/21 | 3/29/22 | 3/28/23 | 3/20/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 702 | 984.2 | 2,860 | 1,942 | 2,328 | 2,240 | 2,317 | 2,702 | 3,505 | 3,728 | 4,119 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | -1,148 | -1,960 | -1,212 | -1,617 | -718.8 | - | -692.6 | -1,020 |
| Operating Margin | - | - | - | -59.12% | -84.17% | -54.11% | -69.8% | -26.61% | - | -18.58% | -24.77% |
| Earnings before Tax (EBT) | - | - | - | - | -1,876 | -998.9 | -1,172 | -256.1 | - | - | - |
| Net income | - | - | - | - | -1,963 | -950.5 | -1,229 | -139.1 | - | - | - |
| Net margin | - | - | - | - | -84.31% | -42.43% | -53.04% | -5.15% | - | - | - |
| EPS 2 | -0.8400 | -0.4600 | -0.2800 | -0.8100 | -1.350 | -0.6500 | -0.8100 | -0.0900 | - | -0.3000 | -0.5100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 8/26/20 | 3/29/21 | 8/25/21 | 3/29/22 | 8/25/22 | 3/28/23 | 8/23/23 | 3/20/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 3,368 | 7,079 | 6,525 | 6,059 | - | 5,026 | 4,367 | 4,616 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -2,030 | -797 | -3,090 | -2,816 | - | -949 | -229 | 1,072 |
| ROE (net income / shareholders' equity) | -38.4% | -14.8% | -32.8% | -20.7% | - | -6.72% | 1.08% | 9.91% |
| ROA (Net income/ Total Assets) | -25.8% | -10.5% | -22.4% | -12.9% | - | -4.12% | 0.61% | 5.75% |
| Assets 1 | 6,672 | 9,533 | 14,039 | 16,916 | - | 20,498 | 24,157 | 25,078 |
| Book Value Per Share 2 | 4.040 | 6.470 | 7.100 | 7.200 | - | 7.550 | 7.340 | 8.030 |
| Cash Flow per Share 2 | -1.410 | -0.2300 | -1.390 | -1.290 | - | -0.2100 | 0.2300 | 1.030 |
| Capex 1 | 366 | 489 | 1,066 | 897 | - | 708 | 740 | 783 |
| Capex / Sales | 34.93% | 12.72% | 24.96% | 19.68% | - | 9.34% | 7.43% | 6.05% |
| Announcement Date | 3/30/20 | 3/29/21 | 3/29/22 | 3/28/23 | 3/20/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
38.28
CNY
Average target price
51.07
CNY
Spread / Average Target
+33.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.16% | 8.62B | |
| -2.61% | 89.08B | |
| +3.55% | 40.9B | |
| -14.40% | 32.25B | |
| +55.89% | 25.14B | |
| -15.96% | 15.39B | |
| -15.50% | 11.91B | |
| -41.29% | 11.89B | |
| -11.75% | 11.64B | |
| +7.87% | 9.03B |
- Stock Market
- Equities
- 1801 Stock
- Financials Innovent Biologics, Inc.
